Ensorcell (ensorcell.bio), a US-based company focused on reimaging life science tools and solutions for the biopharmaceutical industry, announced on Tuesday the appointments of Geoff Hodge and Amy Teachout to its senior leadership team.
Hodge is named head of Technology, responsible for accelerating high impact innovation across the company's technology and product development initiatives. He brings decades of experience spanning biopharmaceutical research, development, manufacturing, and technology leadership from his experience as co-founder of Xcellerex, CEO of SOTIO Biotech, and CTO of Unum Therapeutics. His focus at Ensorcell will be on translating novel concepts into scalable solutions that help partners advance programs efficiently from development through manufacturing.
Teachout has been appointed head of Customer Excellence, with responsibility for ensuring seamless, high-quality customer care across the full client engagement lifecycle. She brings extensive experience in program leadership, commercialisation support, logistics, and customer care.
Jeff Goldman, Ensorcell general manager, said: "Geoff and Amy bring deep industry expertise and complementary leadership strengths. Geoff's focus on accelerating high-impact breakthroughs and Amy's leadership in customer excellence directly support Ensorcell's mission to deliver meaningful, reliable outcomes for our biopharma partners."
Solvonis Therapeutics secures second US patent for PTSD compound series
GSK secures China approval for Exdensur to treat nasal polyp condition
Ondine Biomedical ICU study accepted by Journal of Critical Care
Alzinova partners with Amsterdam UMC to advance blood-based Alzheimer's diagnostic
CenExel appoints Dr. Sy Pretorius as CEO
Insmed reports Phase 2b study of brensocatib did not meet efficacy endpoints
Gilead to acquire Tubulis to expand ADC oncology capabilities
FDA grants Fast Track status to SIM0505 for platinum‑resistant ovarian cancer
Sanofi reports positive phase 2 results for lunsekimig in asthma and CRSwNP
Aelis Farma secures EUR458k France 2030 grant to advance metabolic disease programme
Immedica Pharma gains European approval to extend Efmody use in adrenal insufficiency